natgillin/translations-raw huggingface dataset:
An antigen is a specific structure that the body can recognise as ‘foreign' and against which the body can make an antibody, a special protein that can neutralise or destroy the antigen. 
Antigeni so posebne strukture, ki jih telo lahko prepozna kot „tujek“ in lahko proti njim tvori protitelesa.
Vaccination with RotaTeq should be postponed in babies who have a sudden high fever, diarrhoea or vomiting. 
Cepljenje s cepivom Rotarix je treba preložiti pri dojenčkih, ki imajo nenadno povišano telesno temperaturo, drisko ali bruhajo.
What is the risk associated with RotaTeq? 
Kakšna tveganja so povezana z zdravilom RotaTeq?
The study also showed that there were fewer hospital admissions or visits to emergency clinics for rotavirus gastroenteritis in babies vaccinated with RotaTeq. 
Študija je pokazala tudi, da je bilo v skupini dojenčkov, ki so bili cepljeni s cepivom RotaTeq, manj sprejemov v bolnišnico oziroma obiskov klinik za nujno pomoč zaradi rotavirusnega gastroenteritisa.
RotaTeq must not be given to babies who have had intussusception in the past or who have problems with their bowel that could put them at risk of intussusception. 
Cepivo RotaTeq se ne sme uporabiti pri dojenčkih, ki so imeli uvihanje črevesja v preteklosti, ali pri dojenčkih, ki imajo težave s črevesjem, ki lahko pomenijo nagnjenost k tej bolezni.
Why has RotaTeq been approved? 
Zakaj je bilo zdravilo RotaTeq odobreno?
They vary in that they may carry different antigens. 
Razlikujejo se v antigenih, ki jih nosijo.
RotaTeq is a vaccine that is taken by mouth. 
Zdravilo RotaTeq je cepivo, ki se jemlje peroralno.
What is RotaTeq? 
Kaj je zdravilo RotaTeq?
What is RotaTeq used for? 
Za kaj se zdravilo RotaTeq uporablja?
RotaTeq can be given to premature babies, as long as the pregnancy lasted at least 25 weeks. 
Cepivo lahko prejmejo tudi nedonošenčki, ki so bili rojeni najmanj v 25. tednu nosečnosti.
How has RotaTeq been studied? 
Kako je bilo zdravilo RotaTeq raziskano?
How does RotaTeq work? 
Kako zdravilo RotaTeq deluje?
How is RotaTeq used? 
Kako se zdravilo RotaTeq uporablja?
Ref. EMEA/270168/2008 
EMEA/331188/2008
It was hoped that this would make it easier for patients to stick to their treatment. 
Cilj tega je bil, da bi bilo bolnikom lažje držati se predvidenega zdravljenja.
On 23 May 2008, Bristol Myers Squibb Pharma EEIG officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for DuoCover for the prevention of atherothrombotic events. 
Družba Bristol Myers Squibb Pharma EEIG je dne 23. maja 2008 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za dovoljenje za promet z zdravilom DuoCover, namenjenim za preprečevanje aterotrombotičnih dogodkov.
It was to be available as tablets containing 75 mg clopidogrel plus 75 mg acetylsalicylic acid, and as tablets containing 75 mg clopidogrel plus 100 mg acetylsalicylic acid. 
Naj voljo naj bi bilo v tabletah s 75 mg klopidogrela in 75 mg acetilsalicilne kisline in v tabletah s 75 mg klopidogrela in 100 mg acetilsalicilne kisline.
QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE MARKETING APPLICATION for DUOCOVER 
VPRAŠANJA IN ODGOVORI V ZVEZI Z UMIKOM VLOGE ZA DOVOLJENJE ZA PROMET z zdravilom DUOCOVER
There are no consequences on the use of Iscover/Plavix with acetylsalicylic acid in the authorised indications, for which the balance of benefits and risks remains unchanged. 
Umik nima nobenih posledic za uporabo zdravil Iscover/Plavix z acetilsalicilno kislino za odobreno indikacijo, pri kateri ostaja razmerje med koristmi in tveganji nespremenjeno.
What is DuoCover? 
Kaj je zdravilo DuoCover?
When the blood clots, this is due to special cells in the blood, the platelets, sticking together (aggregating). 
Kri se strjuje zaradi posebnih celic v krvi, trombocitov, ki se zlepljajo (agregirajo) med seboj.
What are the consequences of the withdrawal for patients undergoing clinical trials / compassionate use programmes with DuoCover? 
Kakšne so posledice umika za bolnike, ki sodelujejo v kliničnih preskušanjih ali programih sočutne uporabe z zdravilom DuoCover?
The active substances in DuoCover, clopidogrel and acetylsalicylic acid, are combined into one tablet in DuoCover to reduce the number of tablets the patients need to take every day. 
Zdravilni učinkovini v zdravilu DuoCover, klopidogrel in acetilsalicilna kislina, sta v zdravilu DuoCover kombinirani v eno tableto, da bi s tem zmanjšali število tablet, ki jih mora bolnik jemati vsak dan.
This included patients who were having an acute myocardial infarction (heart attack) with an ‘ST segment elevation' (an abnormal reading on the electrocardiogram or ECG) when the doctor thought that they would have benefited from the treatment. 
Mednje spadajo bolniki, ki so imeli akutni miokardni infarkt (srčni napad) z elevacijo spojnice ST (nenormalni zapis na elektrokardiogramu ali EKG), če bi zdravnik menil, da bi zdravilo lahko bolniku pomagalo.
It was also expected to be used in patients who did not have this abnormal reading on the ECG, if they had unstable angina (a severe type of chest pain) or a ‘non-Q-wave' myocardial infarction and who had a stent inserted (a short tube placed in an artery to prevent it closing up). 
Uporabljalo naj bi se tudi pri bolnikih, ki nimajo tega nenormalnega zapisa na EKG, če imajo nestabilno angino (resno obliko bolečine v prsih) ali miokardni infarkt brez zobca Q in ki jim je bil vstavljen stent (v arterijo vstavljena kratka cevčica, ki preprečuje, da bi se arterija zaprla).
However the CHMP thought that the company could have addressed these concerns and was of the provisional opinion that DuoCover could have been approved for the prevention of atherothrombotic events. 
Vendar pa je Odbor menil, da bi družba na te zadržke lahko odgovorila, in je začasno menil, da bi se zdravilo DuoCover lahko odobrilo za preprečevanje aterotrombotičnih dogodkov.
Furthermore, the studies of Iscover and Plavix used with acetylsalicylic acid as separate tablets were used to support the use of DuoCover in the same indication. 
Poleg tega so bile študije z zdraviloma Iscover in Plavix, uporabljenima skupaj z acetilsalicilno kislino v ločenih tabletah uporabljene v podporo uporabi zdravila DuoCover za enako indikacijo.
The CHMP was concerned that the bioequivalence studies that were carried out did not use the recommended methods and did not provide sufficient evidence that the combined tablet was absorbed in the body in the same way as the two medicines given separately. 
CHMP je skrbelo, da pri izvedenih študijah biološke enakovrednosti niso bile uporabljene priporočene metode in da niso zagotovile zadostnih dokazov, da telo kombinirano tableto absorbira na enak način kot dve ločeno dani zdravili.
Based on the review of the data and the company's responses to the CHMP lists of questions at the time of the withdrawal, the CHMP had some concerns. 
Na podlagi pregleda podatkov in odgovorov družbe na sezname vprašanj, ki jih je do umika vloge zastavil CHMP, je Odbor izrazil določene zadržke.
It was expected to be used to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries) in patients who have a condition known as ‘acute coronary syndrome'. 
Uporabljalo naj bi se za preprečevanje aterotrombotičnih dogodkov (težav, ki jih povzročajo krvni strdki in otrdevanje arterij) pri bolnikih z akutnim koronarnim sindromom.
The company informed the CHMP that there are no consequences for patients who are planned to be included in clinical trials with DuoCover or patients currently included in clinical trials with clopidogrel and acetylsalicylic acid as separate medicines. 
Družba je obvestila CHMP, da umik nima nobenih posledic za bolnike, ki bodo vključeni v klinična preskušanja zdravila DuoCover, ali bolnike, ki že sodelujejo v kliničnih preskušanjih s klopidogrelom in acetilsalicilno kislino kot ločenima zdraviloma.
Clopidogrel on its own has been approved by the EU under the names Iscover and Plavix, for the prevention of atherothrombotic events, in combination with acetylsalicylic acid, in patients with acute coronary syndrome. 
EU je klopidogrel kot samostojno zdravilo odobrila pod imenoma Iscover in Plavix za preprečevanje aterotrombotičnih dogodkov v kombinaciji z acetilsalicilno kislino pri bolnikih z akutnim koronarnim sindromom.
DuoCover was expected to be used in adult patients already taking clopidogrel and acetylsalicylic acid as separate tablets. 
Zdravilo DuoCover naj bi se uporabljalo pri odraslih bolnikih, ki že jemljejo klopidogrel in acetilsalicilno kislino v ločenih tabletah.
What was DuoCover expected to be used for? 
Za kaj naj bi se zdravilo DuoCover uporabljalo?
Therefore, at the time of the withdrawal, the CHMP's view was that the company had not fully addressed their concerns and the benefit of the DuoCover combined tablet compared with the separate medicines had not been demonstrated. 
CHMP je ob umiku menil, da se družba ni v zadostni meri posvetila zadržkom in da korist kombinirane tablete DuoCover v primerjavi z ločenima zdraviloma ni bila dokazana.
How is DuoCover expected to work? 
Kako naj bi zdravilo DuoCover delovalo?
DuoCover is a medicine containing two active substances clopidogrel and acetylsalicylic acid in one tablet. 
Zdravilo DuoCover vsebuje v eni tableti dve zdravilni učinkovini, klopidogrel in acetilsalicilno kislino.
‘bioequivalence' studies to establish whether the combined tablet was absorbed in the body in the same way as the two medicines given separately. 
Družba je v podporo svoji vlogi za zdravilo DuoCover izvedla študijo biološke enakovrednosti, da bi ugotovila, ali telo kombinirano tableto absorbira na enak način kot dve ločeni zdravili.
Elderly (≥ 65 years old) 
Starejši ( ≥ 65 let)
* See Section 4.4. 
* Glejte poglavje 4.4.
It also lowers the amount of sugar made by your body. 
Prav tako zmanjša količino sladkorja, ki nastane v telesu.
• low blood sugar 
• nizek krvni sladkor.
• kidney problems (sometimes requiring dialysis) 
• težave z ledvicami (včasih je potrebna dializa),
It is not known if this medicine passes into breast milk. 
Ni znano, ali to zdravilo prehaja v materino mleko.
Hispanic or Latino patients comprised 15.6% to 36.1% of the population. 
Latinoameričani so predstavljali od 15,6 % do 36,1 % populacije.
Steglujan should be taken orally once daily in the morning, with or without food. 
Zdravilo Steglujan je treba jemati peroralno enkrat na dan zjutraj, s hrano ali brez nje.
• if you are taking digoxin (a medicine used to treat irregular heart beat and other heart problems). 
• če jemljete digoksin (zdravilo, ki se uporablja za zdravljenje nepravilnega bitja srca in drugih težav s srcem).
• Swallow the tablet; if you have difficulties with swallowing the tablet can be broken or crushed. 
• Tableto pogoltnite; če imate težave s požiranjem, lahko tableto prelomite ali zdrobite.
Treatment with Steglujan may be restarted when the ketone values are normal and the patient's condition has stabilised. 
Zdravljenje z zdravilom Steglujan je mogoče znova uvesti, ko so vrednosti ketonov normalne in se bolnikovo stanje stabilizira.
• The dose of Steglujan that you take will depend on your condition and the amount of ertugliflozin and sitagliptin needed to control your blood sugar. 
• Odmerek zdravila Steglujan, ki ga boste jemali, bo odvisen od vašega stanja in količine ertugliflozina in sitagliptina, potrebne za uravnavanje vašega krvnega sladkorja.
The mean age of the patients across these 3 studies ranged from 55.1 to 59.1 years (range 21 years to 85 years). 
Povprečna starost bolnikov v teh 3 študijah je bila od 55,1 do 59,1 leta (razpon od 21 do 85 let).
What you need to know before you take Steglujan 3. 
Kaj morate vedeti, preden boste vzeli zdravilo Steglujan 3.
Patients should not take two doses of Steglujan on the same day. 
Bolnik ne sme vzeti dveh odmerkov zdravila Steglujan na isti dan.
*Incidence rate per 100 patient-years is calculated as 100 × (total number of patients with ≥ 1 event during eligible exposure period per total patient-years of follow-up). 
* Pojavnost na 100 bolnik-let je izračunana kot 100 × (celotno število bolnikov z ≥ 1 dogodkom med ustreznim obdobjem izpostavljenosti na celotno število bolnik-let spremljanja).
Exfoliative skin conditions including Stevens-Johnson syndrome a, 
eksfoliativna stanja na koži, vključno s Stevens-Johnsonovim sindromom a,
Your doctor may decide to temporarily or permanently stop your treatment with Steglujan. 
Zdravnik bo morda odločil, da z zdravljenjem z zdravilom Steglujan začasno ali trajno prenehate.
(For study results with respect to combinations and effects on glycaemic control, see sections 4.4, 4.5, and 5.1) 
(Za rezultate študij glede kombiniranega zdravljenja in učinkov na urejenost glikemije glejte poglavja 4.4, 4.5 in 5.1.)
The effects on kidney and bone did not fully reverse after the 1 month recovery period. 
Vplivi na ledvice in kosti po 1-mesečnem obdobju okrevanja niso povsem izginili.
The European Medicines Agency has waived the obligation to submit the results of studies with Steglujan in all subsets of the paediatric population in the treatment of type 2 diabetes (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Steglujan za vse podskupine pediatrične populacije za zdravljenje sladkorne bolezni tipa 2 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
• Sitagliptin helps to increase the levels of insulin produced after a meal. 
• Sitagliptin pomaga povečati količino insulina, ki nastane po obroku.
Ertugliflozin and sitagliptin are present in the milk of lactating rats. 
Ertugliflozin in sitagliptin sta prisotna v mleku doječih podgan.
• have or have had gallstones, alcohol dependence or very high levels of triglycerides (a form of fat) in your blood. 
• če imate ali ste v preteklosti imeli žolčne kamne, odvisnost od alkohola ali zelo visoko koncentracijo trigliceridov (vrste maščob) v krvi.
There is no information regarding the presence of Steglujan or its individual components in human milk, the effects on the breast-fed infant, or the effects on milk production. 
Glede prisotnosti zdravila Steglujan ali njegovih posameznih sestavin v materinem mleku, njegovih učinkih na dojenega otroka ali njegovih učinkih na nastajanje mleka ni podatkov.
What Steglujan is and what it is used for 2. 
Kaj je zdravilo Steglujan in za kaj ga uporabljamo 2.
Approximately 79% of sitagliptin is excreted unchanged in the urine. 
Približno 79 % sitagliptina se izloči z urinom v nespremenjeni obliki.
Use of dipeptidyl peptidase-4 (DPP-4) inhibitors has been associated with a risk of developing acute pancreatitis. 
Uporaba zaviralcev dipeptidil peptidaze 4 (DPP-4) je povezana s tveganjem za razvoj akutnega pankreatitisa.
• if you are taking other medicines that lower the amount of sugar in your blood, such as insulin or medicines that increase insulin release from the pancreas. 
• če jemljete druga zdravila, ki znižujejo sladkor v krvi, kot so insulin ali zdravila, ki povečajo sproščanje insulina iz trebušne slinavke.
• Steglujan can be used alone or with some other medicines that lower blood sugar. 
• Zdravilo Steglujan se lahko uporablja samostojno ali skupaj s kakšnimi drugimi zdravili za zniževanje krvnega sladkorja.
The safety and efficacy of Steglujan in patients with type 1 diabetes have not been established and Steglujan should not be used for treatment of patients with type 1 diabetes. 
Varnost in učinkovitost zdravila Steglujan pri bolnikih s sladkorno boleznijo tipa 1 nista bili dokazani in se ga ne sme uporabljati za zdravljenje bolnikov s sladkorno boleznijo tipa 1.
• have or have had a disease of the pancreas (such as pancreatitis). 
• če imate ali ste v preteklosti imeli bolezen trebušne slinavke (kot je pankreatitis).
• Severe and persistent pain in the abdomen (stomach area) which might reach through to your back with or without nausea and vomiting, as these could be signs of an inflamed pancreas (pancreatitis). 
• hudo in dolgotrajno bolečino v abdomnu (predelu trebuha), ki se lahko širi tudi v hrbet, s sočasno slabostjo in bruhanjem ali brez tega, saj lahko ti znaki kažejo na vnetje trebušne slinavke (pankreatitis).
• when metformin and/or a sulphonylurea (SU) and one of the monocomponents of Steglujan do not provide adequate glycaemic control. 
• če metformin in/ali sulfonilsečnina in ena od komponent zdravila Steglujan ne zagotavljajo ustrezne urejenosti glikemije.
Because increases of this magnitude are not clinically relevant, dosage adjustment in these patients is not necessary. 
Ker povečanja v tem obsegu niso klinično pomembna, pri teh bolnikih prilagoditev odmerka ni potrebna.
Patients with an eGFR < 30 ml/min/1.73 m2 were not to be enrolled in the study. 
Bolniki z eGFR < 30 ml/min/1,73 m2 niso smeli biti vključeni v študijo.
Resolution of pancreatitis has been observed after discontinuation of sitagliptin (with or without supportive treatment), but very rare cases of necrotising or haemorrhagic pancreatitis and/or death have been reported. 
Opazili so, da je po prenehanju jemanja sitagliptina pankreatitis izzvenel (z ali brez podpornega zdravljenja), v zelo redkih primerih pa so poročali o nekrotizirajočem ali hemoragičnem pankreatitisu in/ali smrti.
The safety and efficacy of Steglujan in children under 18 years of age have not been established. 
Varnost in učinkovitost zdravila Steglujan pri otrocih, mlajših od 18 let, nista bili dokazani.
Across the 3 studies, 16.2% to 29.9% of patients were ≥ 65 years of age and 2.3% to 2.8% were ≥ 75 years of age. 
V teh 3 študijah je bilo od 16,2 do 29,9 % bolnikov starih ≥ 65 let in od 2,3 do 2,8 % ≥ 75 let.
• A serious allergic reaction (frequency not known), including rash, hives, blisters on the skin/peeling skin and swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing. 
• resno alergijsko reakcijo (pogostnost je neznana), ki vključuje izpuščaj, koprivnico, mehurje na koži/luščenje kože in otekanje obraza, ustnic, jezika ter žrela, kar lahko povzroči težave pri dihanju ali požiranju.
Before initiating ertugliflozin/sitagliptin, consider factors in the patient history that may increase the risk for amputation. 
Pred uvedbo ertugliflozina/sitagliptina je treba upoštevati dejavnike iz bolnikove anamneze, ki lahko povečajo tveganje za amputacijo.
The effect of Steglujan on fertility in humans has not been studied. 
Vpliva zdravila Steglujan na plodnost pri ljudeh niso preučevali.
If you take more Steglujan than you should If you take too much Steglujan, talk to a doctor or pharmacist straight away. 
Če ste vzeli večji odmerek zdravila Steglujan, kot bi smeli Če vzamete preveč zdravila Steglujan, se takoj posvetujte z zdravnikom ali farmacevtom.
Rare • reduced number of platelets 
Redki • zmanjšano število krvnih ploščic
Hospitalisation for unstable angina 
Sprejem v bolnišnico zaradi nestabilne angine pektoris
In patients with normal renal function, metabolism, including via CYP3A4, plays only a small role in the clearance of sitagliptin. 
Pri bolnikih z normalnim delovanjem ledvic ima presnova, vključno preko CYP3A4, le majhno vlogo v očistku sitagliptina.
Across the 3 studies, the racial distribution ranged from 72.9% to 90.4% White, 0.0% to 20.3% Asian, 1.9% to 4.5% Black and 4.8% to 5.4% Other. 
V teh 3 študijah je bila rasna porazdelitev naslednja: od 72,9 % do 90,4 % je bilo belcev, od 0,0 % do 20,3 % Azijcev, od 1,9 % do 4,5 % črncev in od 4,8 do 5,4 % drugih.
You should not take this medicine during pregnancy. 
Tega zdravila med nosečnostjo ne smete uporabljati.
There is limited experience with Steglujan in patients ≥ 75 years of age. 
Podatkov glede izkušenj z zdravilom Steglujan pri bolnikih, starih ≥ 75 let, je malo.
However, when driving or using machines, it should be taken into account that dizziness and somnolence have been reported with sitagliptin. 
Vendar pa je treba pri vožnji ali upravljanju strojev upoštevati, da so pri uporabi sitagliptina poročali o omotici in zaspanosti.
What you need to know before you take Steglujan 
Kaj morate vedeti, preden boste vzeli zdravilo Steglujan
The incidence and type of adverse reactions in these three studies were similar to the adverse reactions seen with ertugliflozin and are described below in Table 1. 
Pojavnost in vrsta neželenih učinkov iz teh treh študij sta bili podobni neželenim učinkom za ertugliflozin in so opisani spodaj v preglednici 1.
Because of the high safety margin (19-fold at this no-effect level), these neoplastic changes are not considered relevant for the situation in humans. 
Zaradi visoke meje varnosti (19-kratna izpostavljenost brez škodljivega učinka) teh neoplastičnih sprememb nimamo za pomembne pri klinični uporabi pri človeku.
These medical conditions can increase your chance of getting pancreatitis (see section 4). 
Ta zdravstvena stanja lahko povečajo možnost za pojav pankreatitisa (glejte poglavje 4).
It is not known if Steglujan can harm your unborn baby. 
Ni znano, ali lahko zdravilo Steglujan škoduje nerojenemu otroku.
Elderly subjects (65 to 80 years) had approximately 19% higher plasma concentrations of sitagliptin compared to younger subjects. 
Pri starejših bolnikih (65 do 80 let) so bile plazemske koncentracije sitagliptina približno za 19 % večje kot pri mlajših osebah.
If you forget to take Steglujan 
Če ste pozabili vzeti zdravilo Steglujan
Stop taking Steglujan and contact a doctor straight away if you notice any of the following serious side effects: 
Prenehajte jemati zdravilo Steglujan in se takoj posvetujte z zdravnikom, če opazite katerega koli od naslednjih resnih neželenih učinkov:
Steglujan should not be used to treat this condition. 
Zdravila Steglujan se ne sme uporabljati za zdravljenje te bolezni.
Effects of other medicinal products on sitagliptin 
Vpliv drugih zdravil na sitagliptin
If Fournier's gangrene is suspected, Steglujan should be discontinued and prompt treatment (including antibiotics and surgical debridement) should be instituted. 
Če obstaja sum na Fournierjevo gangreno, je treba zdravilo Steglujan ukiniti in uvesti takojšnje zdravljenje (vključno z antibiotiki in kirurško odstranitvijo prizadetega tkiva).
Analysis in the Intention-to-Treat Population 
Analiza populacije z namenom zdravljenja
• take other diabetes medicines: you are more likely to get low blood sugar with certain medicines. 
• če jemljete druga zdravila za sladkorno bolezen: pri določenih zdravilih imate večjo verjetnost za pojav nizkega krvnega sladkorja.
Ertugliflozin in combination with sitagliptin 
Ertugliflozin v kombinaciji s sitagliptinom
• osteoarthritis 
• osteoartritis,
The improvement in glycaemic control observed with this medicinal product may be mediated by enhancing the levels of active incretin hormones. 
Izboljšanje urejenosti glikemije, ki so ga opazili pri tem zdravilu, je lahko posledica povečanja količine aktivnih hormonov inkretinov.
Following administration of 0.25 mg digoxin concomitantly with 100 mg of sitagliptin daily for 10 days, the plasma AUC of digoxin was increased on average by 11% and the plasma Cmax on average by 18%. 
Po 10-dnevnem odmerjanju 0,25 mg digoksina v kombinaciji s 100 mg sitagliptina dnevno se je vrednost AUC digoksina v plazmi povečala povprečno za 11 %, vrednost Cmax pa povprečno za 18 %.
In clinical studies, approximately 13.5% of the dose was removed over a 3- to 4-hour haemodialysis session. 
V kliničnih študijah se je med 3- do 4-urno hemodializo odstranilo približno 13,5 % odmerka.
In patients with type 2 diabetes treated with ertugliflozin in combination with sitagliptin, the improvement in HbA1c was similar across subgroups defined by age, sex, and race, and duration of type 2 diabetes mellitus. 
Pri bolnikih s sladkorno boleznijo tipa 2, zdravljenih z ertugliflozinom v kombinaciji s sitagliptinom, je bilo izboljšanje HbA1c pri podskupinah, opredeljenih glede na starost, spol in raso in trajanje sladkorne bolezni tipa 2 podobno.